Cryosite Limited (ASX:CTE) is an Australian company specialising in temperature-controlled storage and logistics solutions for the life sciences and pharmaceutical industries, in particular for clinical trials and biological materials. CTE has released its H1 FY26 results which show an acceleration in growth. Revenue was up 24.6% on the previous corresponding period (pcp) while EBITDA was up 32.5% on the pcp. EBITDA margins also expanded to 24.3% from 22.9% in the pcp. All segments grew, while the standout again was the Ultra-Frozen and Cryogenic segment with 63.1% revenue growth on the pcp. Cash flows from operating activities were up 30.2%. During the period, CTE completed the acquisition of its new freehold facility at 100-104 Adderley Street West, Auburn, NSW; this site provides critical capacity for CTE to meet growing demand and as we’ve highlighted in our reporting previously, we expect a strong ROCE from this investment.
